This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AstraZeneca (AZN) to Report Q4 Earnings: Here's What to Expect
by Zacks Equity Research
Sales of AstraZeneca's (AZN) key drugs like Imfinzi and Farxiga are expected to have been boosted by approvals in new indications.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Merck (MRK) Q4 Earnings Beat, Sales Miss, Upbeat '24 View
by Zacks Equity Research
Merck (MRK) beats Q4 estimates for earnings but misses the mark on sales. The company issues an encouraging 2024 guidance. Stock rises in pre-market.
Sanofi (SNY) Misses on Q4 Earnings and Sales, Stock Down
by Zacks Equity Research
Sanofi (SNY) misses fourth-quarter estimates for earnings and sales. It maintains 2024 earnings growth guidance.
Astrazeneca (AZN) Stock Moves -0.83%: What You Should Know
by Zacks Equity Research
Astrazeneca (AZN) closed the most recent trading day at $66.64, moving -0.83% from the previous trading session.
Eli Lilly (LLY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Eli Lilly's (LLY) fourth-quarter conference call, investor focus is likely to be on the sales performance of its tirzepatide medicines, Mounjaro and Zepbound.
AbbVie (ABBV) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
AbbVie's (ABBV) Q4 performance will likely reflect its newer immunotherapy drugs trying to compensate for declining Humira sales following the loss of U.S. exclusivity.
AstraZeneca's (AZN) sBLA for Enhertu Gets FDA's Priority Tag
by Zacks Equity Research
AstraZeneca's (AZN) sBLA for Enhertu to treat metastatic HER2-positive solid tumors gets priority review status by the FDA. A final decision is expected in second-quarter 2024.
GSK Gears Up for Q4 Earnings: Will It Surpass Estimates?
by Zacks Equity Research
We expect GSK's specialty products like Arexvy, Cabenuva, Dovato, Bexsero, Trelegy Ellipta and Shingrix to drive fourth-quarter sales performance.
Novo Nordisk (NVO) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Novo Nordisk's (NVO) sales in fourth-quarter 2023 are expected to have been driven by increased Diabetes and Obesity Care product sales despite pricing pressure in the United States.
Can Amgen (AMGN) Keep the Beat Streak Alive in Q4 Earnings?
by Zacks Equity Research
Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Astrazeneca (AZN) Laps the Stock Market: Here's Why
by Zacks Equity Research
In the latest trading session, Astrazeneca (AZN) closed at $67.02, marking a +0.63% move from the previous day.
Can Merck (MRK) Keep the Beat Streak Alive in Q4 Earnings?
by Zacks Equity Research
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports fourth-quarter earnings.
Pfizer (PFE) to Report Q4 Earnings: Here's What to Expect
by Zacks Equity Research
Pfizer's (PFE) revenues are expected to have declined in the fourth quarter of 2023 due to a steep decline in sales of its COVID-19 products on lower demand.
AstraZeneca PLC (AZN) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Astrazeneca (AZN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
AstraZeneca's (AZN) Imfinzi Combo Meets Liver Cancer Study Goal
by Zacks Equity Research
Data from a late-stage shows that AstraZeneca's (AZN) cancer combination therapy reduces the risk of disease progression or death in certain liver cancer patients by 23%.
Will the Individual MA Unit Aid Humana's (HUM) Q4 Earnings?
by Zacks Equity Research
Humana's (HUM) Q4 results are likely to gain from growing premiums and an expanding customer base within its individual Medicare Advantage and Medicaid units, partly offset by higher marketing spend.
Here's Why Astrazeneca (AZN) is a Strong Momentum Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
The Zacks Analyst Blog Highlights Microsoft, Procter & Gamble, AstraZeneca, General Electric and Boston Scientific
by Zacks Equity Research
Microsoft, Procter & Gamble, AstraZeneca, General Electric and Boston Scientific are included in this Analyst Blog.
Here's Why Astrazeneca (AZN) Gained But Lagged the Market Today
by Zacks Equity Research
In the closing of the recent trading day, Astrazeneca (AZN) stood at $66.54, denoting a +0.03% change from the preceding trading day.
Top Research Reports for Microsoft, Procter & Gamble & AstraZeneca
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), The Procter & Gamble Company (PG) and AstraZeneca PLC (AZN).
Astrazeneca (AZN) is a Top-Ranked Value Stock: Should You Buy?
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
J&J (JNJ) Gears Up to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
J&J's (JNJ) Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. Surgical procedure recovery and new products are likely to have driven MedTech sales.
Astrazeneca (AZN) Rises Yet Lags Behind Market: Some Facts Worth Knowing
by Zacks Equity Research
Astrazeneca (AZN) closed the most recent trading day at $66.52, moving +0.41% from the previous trading session.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.